Being a CYP2D6 ultrarapid metabolizer can turn an ordinary prescription into a problem, most famously with codeine and tramadol. Below you will find what causes this result, the warning signs to know, which medicines are affected and how to use the result safely with your prescriber.
On this page
Cytochrome P450 2D6, commonly referred to as CYP2D6 is one of the key enzymes in the liver responsible for metabolizing approximately 25% of clinically used medications. Ultrarapid metabolizers have an increased rate of converting prodrugs, such as codeine and tramadol, into their active forms (morphine and O-desmethyltramadol, respectively). This rapid conversion can lead to a sudden and excessive accumulation of the active drug in the bloodstream.
CYP2D6 ultrarapid metabolizer symptoms include (not limited to) opioid toxicity (when opioids requiring activation by cyp2d6 are consumed), which may include severe sedation and respiratory depression. On the other hand, with drugs that are directly active and don’t require metabolic activation, ultrarapid metabolizers may clear the medication too quickly, leading to reduced therapeutic effects and potentially requiring higher doses.
This enzyme plays a pivotal role in breaking down various drug classes, including antidepressants, opioids, beta-blockers, and antipsychotics. CYP2D6 is highly polymorphic, meaning that its activity varies significantly among individuals due to genetic differences. People have different versions of the CYP2D6 gene, resulting in varying enzyme activity levels. Based on their genetic makeup, individuals can be categorized as poor, intermediate, extensive (normal), or ultrarapid metabolizers.
Some medications might not be suitable for you while you may be a poor or rapid metabolizer of others, thus, a PGx test giving genome insights can save you from trial and error.
What Does CYP2D6 Ultrarapid Metabolizer Mean?
A CYP2D6 ultrarapid metabolizer (UM) is someone whose body processes drugs metabolized by CYP2D6 at an accelerated rate. This happens due to multiple active copies of the CYP2D6 gene, leading to higher-than-normal enzyme activity.
While being an ultrarapid metabolizer might sound advantageous, it can actually create problems with certain medications. Drugs that require activation by CYP2D6 may become overly potent, leading to an increased risk of side effects. On the other hand, medicines that need to stay in the bloodstream longer to be effective may be eliminated too quickly, resulting in reduced therapeutic benefit.
CYP2D6 Ultrarapid Metabolizer Symptoms Explained
Ultrarapid metabolizers may experience different symptoms depending on the type of medication they are taking. Here’s a breakdown of how it affects various drug categories:
1. Opioids (e.g., Codeine, Tramadol)
Codeine and tramadol require activation by CYP2D6 to convert into their active forms (morphine and O-desmethyl tramadol, respectively). In ultrarapid metabolizers, this conversion happens too quickly, potentially leading to dangerously high levels of the active drug in the bloodstream. This can result in:
- Excessive sedation
- Respiratory depression (in severe cases)
- Increased risk of opioid toxicity, even at standard doses
2. Antidepressants (e.g., Amitriptyline, Nortriptyline, Vortioxetine)
CYP2D6 processes many antidepressants. In UMs, these drugs may be cleared from the body too rapidly, resulting in subtherapeutic levels and inadequate symptom relief. Symptoms include:
- Persistent depressive symptoms
- Poor response to antidepressant therapy
- Need for a dose change or an alternative medicine to achieve the desired effect
3. Beta-Blockers (e.g., Metoprolol)
Beta-blockers are commonly used to manage hypertension and heart conditions. UMs may metabolize these drugs too quickly, leading to insufficient blood pressure control or ineffective treatment of heart rate irregularities.
4. Antipsychotics (e.g., Risperidone, Haloperidol)
For drugs like risperidone, which are metabolized by CYP2D6, ultrarapid metabolism can reduce therapeutic efficacy. This can result in:
- Persistent psychotic symptoms
- Poor treatment outcomes
Can Pharmacogenomics Help CYP2D6 Ultrarapid Metabolizers?
Pharmacogenomics (PGx) testing can be highly beneficial for CYP2D6 ultrarapid metabolizers. PGx testing analyzes your genetic profile to identify how your body processes medications, helping healthcare providers tailor treatment plans that are both safe and effective.
Benefits of PGx Testing for CYP2D6 UMs:
1. Personalized Medication Selection:
Based on PGx test results, physicians can choose alternative medications not primarily metabolized by CYP2D6, reducing the risk of side effects or therapeutic failure.
2. Optimized Dosing:
For drugs that are essential and metabolized by CYP2D6, the PGx test can help determine the right dose to maintain effective blood concentration levels without causing toxicity.
3. Avoiding Trial and Error:
Traditionally, prescribing the right medication involves a trial-and-error approach, which can be time-consuming and frustrating for patients and providers. PGx testing can reduce some of this guesswork and may help your prescriber find an effective treatment sooner.
4. Preventing Adverse Drug Reactions (ADRs):
Since ultrarapid metabolizers are at increased risk of ADRs, especially with opioids, having prior knowledge through PGx testing can prevent serious complications.
CYP2D6 gene duplication: the usual cause of ultrarapid status
Most genes come in two copies, one from each parent. CYP2D6 is unusual because some people carry three or more working copies on the same chromosome.
This is called a CYP2D6 gene duplication (or copy number gain), and it is the most common reason someone ends up as a CYP2D6 ultrarapid metabolizer.
Reports write a duplication with an “x” after the star allele. For example, *1×2 means two copies of the normal-function *1 allele on one chromosome. A genotype such as *1/*1×2 gives three working copies in total, which means more enzyme and faster processing of CYP2D6 drugs.
Not every duplication raises activity. If the duplicated copy is a no-function allele, such as *4×2, it adds nothing. That is why labs need to know both how many copies you have and which versions are duplicated. You can look up any CYP2D6 allele at PharmVar, the official catalog.
A CYP2D6 gene duplication is inherited. If you have one, a parent, child or sibling may also carry it, which is worth mentioning to family members who take pain medicine.
How the CYP2D6 activity score sorts you into a phenotype
Labs turn your genotype into a phenotype using a simple sum called the CYP2D6 activity score. Each allele gets a value based on how well it works, and the values of all your copies are added together.
- Normal-function alleles (such as *1 and *2) count as 1.
- Decreased-function alleles count as 0.5, and *10 counts as 0.25.
- No-function alleles (such as *4 and *5) count as 0.
- Duplicated alleles are counted once for each copy.
Under current CPIC standards, a CYP2D6 activity score above 2.25 is classed as ultrarapid. A score from 1.25 to 2.25 is normal, 0.25 to 1 is intermediate, and 0 is poor. So *1/*1×2 scores 3 and is ultrarapid, while *1/*2 scores 2 and is normal.
Knowing your CYP2D6 activity score is helpful because some guidelines refer to the score rather than the label. If your report only shows the phenotype, ask the lab or pharmacist for the score too.
Codeine and tramadol: why the FDA restricts them
Codeine and tramadol are prodrugs. CYP2D6 turns codeine into morphine and tramadol into O-desmethyltramadol, and those products do most of the pain relief. In a CYP2D6 ultrarapid metabolizer, this conversion runs fast, so active drug can build up to unsafe levels after a normal dose.
After reports of serious breathing problems and deaths, several of them in children who were ultrarapid metabolizers, the FDA added strong warnings. Codeine and tramadol are contraindicated in children under 12, and in children under 18 after tonsil or adenoid surgery. The FDA also advises against both drugs while breastfeeding, because a mother who converts quickly can pass extra active drug to her baby through milk.
For adults who are known ultrarapid metabolizers, CPIC guidelines recommend avoiding codeine and tramadol and choosing a pain medicine that does not depend on CYP2D6 activation, which can include a non-opioid option. Your prescriber picks the specific alternative based on your pain, kidney and liver function and other medicines.
This is the single most important reason to know your status. If you are a CYP2D6 ultrarapid metabolizer, add “avoid codeine and tramadol” to your allergy and intolerance list so every pharmacy and hospital sees it.
Warning signs of opioid toxicity and what to do
Opioid toxicity from fast conversion usually shows up within hours of a dose, and it can happen at a standard prescribed amount. Knowing the signs helps you, your family and caregivers act quickly.
- Unusual sleepiness or being very hard to wake up
- Confusion or slurred speech
- Slow, shallow or noisy breathing
- Very small (pinpoint) pupils
- Blue or gray lips or fingertips
- Limp body or no response to voice or touch
Breathing problems from opioid toxicity are a medical emergency. Call 911 right away. If naloxone is available, use it as directed while you wait for help. In a breastfed baby, watch for extra sleepiness, trouble feeding, limpness or breathing difficulty, and get emergency care if you see them.
Milder signs such as nausea, dizziness or heavy drowsiness after a small dose of either opioid are also worth reporting to your prescriber. They may point to fast conversion even if you have never been tested.
Other medicines with CYP2D6 ultrarapid metabolizer guidance
Opioids get the headlines, but a CYP2D6 ultrarapid metabolizer can also clear some active drugs too quickly, which can make them work poorly. Published guidance covers several of these.
- Ondansetron (for nausea): CPIC suggests prescribers consider an antiemetic less dependent on CYP2D6, such as granisetron, because ondansetron may be less effective.
- Tricyclic antidepressants such as amitriptyline and nortriptyline: guidelines suggest avoiding them in ultrarapid metabolizers or, if used, guiding the dose with blood levels.
- Some SSRIs, including paroxetine and vortioxetine: faster clearance may mean a weaker response, so an alternative may be considered.
- Some antipsychotics such as aripiprazole and risperidone: labels and guidelines discuss CYP2D6 status, mainly for poor metabolizers, but a fast clearer may need closer follow-up.
Drug labels carry this information too. The FDA table of pharmacogenomic biomarkers lists many CYP2D6 medicines, and our medication list shows which genes affect each drug. Only your prescriber can decide whether a change makes sense for you.
When other drugs change your CYP2D6 activity
Your genes set your starting point, but other medicines can move it. Strong CYP2D6 inhibitors such as fluoxetine, paroxetine and bupropion can block the enzyme enough that a genetic ultrarapid metabolizer behaves like a normal or even poor metabolizer. This shift is called phenoconversion.
Phenoconversion cuts both ways. While you take the inhibitor, CYP2D6 prodrug painkillers may give you less relief than expected. If the inhibitor is stopped, your fast activity returns, and a dose that seemed fine before could suddenly act much stronger.
This is why your pharmacist needs a complete list of your prescriptions, over-the-counter drugs and supplements. Our guide to CYP2D6 inhibitors lists the common ones and explains how they work.
Testing for a CYP2D6 gene duplication and reading your report
A pharmacogenomic test checks your CYP2D6 variants and, ideally, how many copies of the gene you carry. Because a CYP2D6 gene duplication is the main route to ultrarapid status, ask any lab whether its test measures copy number. Without it, a duplication can be missed.
The RPh Labs at-home PGx kit uses a simple cheek swab and tests CYP2D6 as part of a 20-gene panel reported against 240+ medications. Results come 7 to 10 business days after the sample reaches our CLIA-certified Dallas lab, and a PharmD pharmacist reviews every report. A free pharmacist consultation is included if you want help reading it.
When your report arrives, look for three items:
- Your CYP2D6 genotype, including any copy number notation such as x2.
- Your CYP2D6 activity score and phenotype.
- The drugs flagged for your phenotype, with a short summary of the guidance.
Your genotype will not change, so this one test can guide prescriptions for the rest of your life.
Everyday steps to stay safe with your result
Once you know your status, a few simple habits make the result work for you long after the report arrives.
- Save a copy of your report on your phone and in a paper folder with your medical records.
- Ask each pharmacy you use to add your CYP2D6 phenotype to your profile, so their software can flag risky fills.
- Check the labels of cough and cold products, because some prescription cough syrups contain codeine.
- Before any surgery, dental extraction or emergency visit, tell the team you are a fast CYP2D6 metabolizer.
- Keep an updated list of every medicine and supplement you take, including doses.
It also helps to review your result whenever a new medicine is started. A drug you take today may have no CYP2D6 link, but the next one might. Pharmacists are well placed to spot these connections, so ask them to check new prescriptions against your report.
Guidelines are updated as research grows, so the advice attached to your genotype can change even though your genes do not. RPh Labs updates reports when guidelines change, and you can ask a pharmacist to recheck your results at any time.
Talking to your prescriber as a CYP2D6 ultrarapid metabolizer
A result only protects you if the people prescribing for you know about it. Share the full report with your primary care clinician, pharmacist, dentist and any surgeon before a procedure, since those are the settings where short courses of opioid pain medicine are often prescribed.
Never stop or switch a medicine on your own because of a gene result. PGx is one piece of the picture, alongside your age, kidney and liver function, other illnesses and other drugs. Useful questions include:
- Can you record my CYP2D6 status in my chart and allergy list?
- Do any of my current medicines depend on CYP2D6?
- What pain medicine would you use for me after surgery or dental work?
- Should my children or siblings think about testing?
If you have questions about the test itself, our FAQ page covers sample collection, timing and privacy.
Conclusion
CYP2D6 ultrarapid metabolizer symptoms may differ upon consuming different medications. PGx testing helps doctors select the right drug and correct doses based on your unique genome by providing insight into how your body processes different drugs. If you suspect you may be a CYP2D6 ultrarapid metabolizer or have experienced unusual responses to medications, consulting with a healthcare professional about PGx testing could be vital for your treatment plan.
References:
https://pmc.ncbi.nlm.nih.gov/articles/PMC5533497/
https://www.medsafe.govt.nz/profs/PUArticles/Mar2013Codeine.htm
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.624104/full
https://www.sciencedirect.com/topics/nursing-and-health-professions/cyp2d6
CYP2D6 ultrarapid metabolizer FAQ
How common is it to be a CYP2D6 ultrarapid metabolizer?
It varies a lot by ancestry. Ultrarapid status is uncommon in many populations but more frequent in some groups, including people with North African, Middle Eastern and Oceanian ancestry. Because you cannot tell from symptoms alone, a pharmacogenomic test is the only reliable way to know your status.
Can I take codeine and tramadol if I am an ultrarapid metabolizer?
Current CPIC guidance recommends avoiding both, because fast conversion can raise active drug levels and cause opioid toxicity. Your prescriber can choose a pain medicine that does not rely on CYP2D6 activation. Do not change any prescription without talking to your prescriber first.
What CYP2D6 activity score counts as ultrarapid?
Under current CPIC standards, a CYP2D6 activity score above 2.25 is ultrarapid. The score adds up the value of each copy you carry, so extra working copies from a duplication push the total higher. Ask your lab or pharmacist for your score if your report only lists a phenotype.
Is a CYP2D6 gene duplication inherited?
Yes. A duplication sits on one chromosome and can be passed from parent to child, so relatives may share it. If you are ultrarapid, it can be worth telling family members, especially before they are prescribed codeine or tramadol for surgery, dental work or an injury.
What should I do if I notice signs of opioid toxicity?
Extreme sleepiness, slow or shallow breathing, pinpoint pupils or blue lips are an emergency. Call 911 right away and use naloxone if it is available. For milder effects such as heavy drowsiness or dizziness after a small dose, contact your prescriber promptly.
Does being an ultrarapid metabolizer affect antidepressants?
It can. Some antidepressants, such as paroxetine, vortioxetine and several tricyclics, may be cleared faster, which can mean a weaker response at usual doses. Guidelines suggest prescribers consider alternatives or dose checks in some cases. Your prescriber weighs this with your history and other medicines.
Leave a Reply